233 related articles for article (PubMed ID: 32806876)
1. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
Kobayashi T; Ito H; Ashida T; Yokoyama T; Nagahori M; Inaba T; Shikamura M; Yamaguchi T; Hori T; Pinton P; Watanabe M; Hibi T
Intest Res; 2021 Oct; 19(4):448-460. PubMed ID: 32806876
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
Motoya S; Watanabe K; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
PLoS One; 2019; 14(2):e0212989. PubMed ID: 30807613
[TBL] [Abstract][Full Text] [Related]
6. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
[TBL] [Abstract][Full Text] [Related]
7. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study).
Hibi T; Imai Y; Senoo A; Ohta K; Ukyo Y
J Gastroenterol; 2017 Oct; 52(10):1101-1111. PubMed ID: 28324167
[TBL] [Abstract][Full Text] [Related]
9. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
D'Haens G; Rosario M; Polhamus D; Dirks NL; Chen C; Kisfalvi K; Agboton C; Vermeire S; Feagan BG; Sandborn WJ
Expert Rev Clin Pharmacol; 2024 Apr; 17(4):403-412. PubMed ID: 38441048
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
[TBL] [Abstract][Full Text] [Related]
11. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Infliximab (CT-P13) as Maintenance Therapy for Inflammatory Bowel Disease: 2 Randomized Phase 3 Trials.
Hanauer SB; Sands BE; Schreiber S; Danese S; Kłopocka M; Kierkuś J; Kulynych R; Gonciarz M; Sołtysiak A; Smoliński P; Srećković S; Valuyskikh E; Lahat A; Horyński M; Gasbarrini A; Osipenko M; Borzan V; Kowalski M; Saenko D; Sardinov R; Lee SJ; Kim S; Bae Y; Lee S; Lee S; Lee JH; Yang S; Lee J; Lee J; Kim JM; Park G; Sandborn WJ; Colombel JF
Gastroenterology; 2024 May; ():. PubMed ID: 38788861
[TBL] [Abstract][Full Text] [Related]
13. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1.
Loftus EV; Sands BE; Colombel JF; Dotan I; Khalid JM; Tudor D; Geransar P
Clin Exp Gastroenterol; 2020; 13():211-220. PubMed ID: 32606883
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study.
Hibi T; Motoya S; Ashida T; Sai S; Sameshima Y; Nakamura S; Maemoto A; Nii M; Sullivan BA; Gasser RA; Suzuki Y
Intest Res; 2019 Jul; 17(3):375-386. PubMed ID: 30739435
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study.
Ooi CJ; Hilmi IN; Kim HJ; Jalihal U; Wu DC; Demuth D; Lindner D; Adsul S
Intest Res; 2021 Jan; 19(1):71-82. PubMed ID: 32877600
[TBL] [Abstract][Full Text] [Related]
18. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
19. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.
Hu Q; Tang XZ; Liu F; Liu DW; Cao B
Therap Adv Gastroenterol; 2023; 16():17562848231166227. PubMed ID: 37124368
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
